Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, Arstila P, Porkka K, Mustjoki S. Kreutzman A, et al. Among authors: rohon p. PLoS One. 2011;6(8):e23022. doi: 10.1371/journal.pone.0023022. Epub 2011 Aug 9. PLoS One. 2011. PMID: 21857985 Free PMC article.
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, Vapaatalo M, Remes K, Lundán T, Hjorth-Hansen H, Vakkila J, Simonsson B, Mustjoki S, Porkka K. Koskenvesa P, et al. Among authors: rohon p. Eur J Haematol. 2014;92(5):413-20. doi: 10.1111/ejh.12258. Epub 2014 Jan 28. Eur J Haematol. 2014. PMID: 24372965
Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.
Mustjoki S, Rohon P, Rapakko K, Jalkanen S, Koskenvesa P, Lundán T, Porkka K. Mustjoki S, et al. Among authors: rohon p. Leukemia. 2010 Jan;24(1):219-22. doi: 10.1038/leu.2009.190. Epub 2009 Sep 24. Leukemia. 2010. PMID: 19776759 No abstract available.
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P, Faber E, Divoka M, Rozmanova S, Friedecky D, Jarosova M, Indrak K. Rohon P, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Jun;157(2):181-8. doi: 10.5507/bp.2011.059. Epub 2011 Nov 30. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013. PMID: 22660209 Free article.
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.
Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, Zach J, Novak M, Marinov I, Soverini S, Faber E, Machova Polakova K. Polivkova V, et al. Among authors: rohon p. PLoS One. 2016 May 23;11(5):e0155959. doi: 10.1371/journal.pone.0155959. eCollection 2016. PLoS One. 2016. PMID: 27214026 Free PMC article.
32 results